Stocktoria

Amneal Pharmaceuticals, Inc. AMRX

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2009-11-18
Chart by TradingView
7/9
Piotroski F — financial health
2.06
Altman Z″ — distress risk · grey
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$3.0B$2.8B$2.4B$2.2B$2.1B
Gross profit$1.1B$1.0B$820.6M$784.7M$769.0M
Operating income$394.1M$249.3M$204.4M-$94.9M$152.7M
Net income$72.1M-$116.9M-$84.0M-$270.6M$13.2M
Operating cash flow$340.0M$295.1M$345.6M$65.1M$241.8M
Free cash flow$269.9M$243.2M$302.4M$18.7M$194.1M
Total assets$3.7B$3.5B$3.5B$3.8B$3.9B
Shareholders' equity-$71.3M-$109.5M$20.0M$184.0M$360.3M
Ratios
Gross margin36.9%36.5%34.3%35.5%36.7%
Operating margin13.1%8.9%8.5%-4.3%7.3%
Net margin2.4%-4.2%-3.5%-12.2%0.6%
FCF margin8.9%8.7%12.6%0.8%9.3%
Return on assets2.0%-3.3%-2.4%-7.1%0.3%
Return on equity-101.0%106.7%-419.7%-147.1%3.7%
Debt / equity-36.06×-19.74×120.94×14.09×7.44×
Current ratio2.171.411.631.882.24
Revenue growth8.0%16.7%8.2%5.7%5.1%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC276,637$3.4M
Point72 Asset Management, L.P.78,105$970,845

Why these scores methodology →

Piotroski F-score: 7/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 2.06 (grey)

  • Working capital / assets 0.28
  • Retained earnings / assets -0.145
  • EBIT / assets 0.107
  • Equity / liabilities -0.019

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001723128 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.